

DAFTAR PUSTAKA

- Adams, B.D., Kasinski, A.L., Slack, F.J., 2015. Aberrant Regulation and Function of MicroRNAs in Cancer. *Curr Biol.* 24: 762–776.
- Agnihotri, S.A., Mallikarjuna, N.N., Aminabhavi, T.M., 2004. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. *J. Control. Release* 100: 5–28.
- Ananta, J.S., Paulmurugan, R., Massoud, T.F., 2016. Tailored nanoparticle codelivery of antimiR-21 and antimiR-10b augments glioblastoma cell kill by temozolomide: Toward a “personalized” anti-microRNA therapy. *Mol. Pharm.* 13: 3164–3175.
- Anwar, S.L., Haryono, S.J., Aryandono, T., Haryana, S.M., 2017. Micro-RNA : Biogenesis, Fungsi, dan Perannya dalam Proses Karsinogenesis dan Penatalaksanaan Kanker. Gadjah Mada University Press, Yogyakarta.
- Bader, A.G., Brown, D., Winkler, M., 2010. The promise of microRNA replacement therapy. *Cancer Res.* 70: 7027–7030.
- Bartel, D.P., 2004. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cell* 116: 281–297.
- Battista, M.J., Schmidt, M., Jakobi, S., Cotarelo, C., Almstedt, K., Heimes, A.S., Makris, G.M., Weyer, V., Lebrecht, A., Hoffmann, G., Eichbaum, M., 2016. C-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients. *Oncol. Lett.* 12: 2001–2007.
- Bayrak, O.F., Gulluoglu, S., Aydemir, E., Ture, U., Acar, H., Atalay, B., Demir, Z., Sevli, S., Creighton, C.J., Ittmann, M., Sahin, F., Ozen, M., 2013. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. *J. Neurooncol.* 115: 143–151.
- Beg, M.S., Brenner, A.J., Sachdev, J., Borad, M., Kang, Y.K., Stoudemire, J., Smith, S., Bader, A.G., Kim, S., Hong, D.S., 2017. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. *Invest. New Drugs* 35: 180–188.
- Bell, D.A., 2005. Origins and molecular pathology of ovarian cancer. *Mod. Pathol.* 18: 19–32.
- Bindewald, E., & Shapiro, B., 2017. RNA Nano- structures. Springer Nature, New York.
- Brahimi-Horn, M.C., Chiche, J., Pouyssegur, J., 2007. Hypoxia and cancer. *J. Mol. Med.* 85: 1301–1307.

- Brett M., R., Jennifer B., P., Thomas A., S., Brett M., R., Jennifer B., P., Thomas A., S., 2017. Epidemiology of ovarian cancer: a review. *Cancer Biol. Med.* 14: 9–32.
- Brown, D.M., Croce, C., Nana-Sinkam, S.P., 2017. Clinical and Therapeutic Application of MicroRNA in Cancer, in: Laurence, J. (Ed.), *Translating MicroRNAs To The Clinic*. Mica Haley, New York, pp. 17–37.
- Brueckner, B., Stresemann, C., Kuner, R., Mund, C., Musch, T., Meister, M., Sultmann, H., Lyko, F., 2007. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. *Cancer Res.* 67: 1419–1423.
- Bruning, U., Cerone, L., Neufeld, Z., Fitzpatrick, S.F., Cheong, a., Scholz, C.C., Simpson, D. a., Leonard, M.O., Tambuwala, M.M., Cummins, E.P., Taylor, C.T., 2011. MicroRNA-155 Promotes Resolution of Hypoxia-Inducible Factor 1 Activity during Prolonged Hypoxia. *Mol. Cell. Biol.* 31: 4087–4096.
- Cao, L., Xie, B., Yang, X., Liang, H., Jiang, X., Zhang, D., Xue, P., Chen, D., Shao, Z., 2015. MIR-324-5p suppresses hepatocellular carcinoma cell invasion by counteracting ECM degradation through post-transcriptionally downregulating ETS1 and SP1. *PLoS One* 10: 1–16.
- Chasanah, S.N., Fitriawan, A.S., Pukan, F.K., Kartika, A.I., 2016. The expression of miRNA-155 and hypoxia inducible factor alpha (HIF1A) mRNA in the early and advanced stages of ovarian cancer patients blood plasma. *Suppl. J Med Sci.* 48: 2016.
- Chen, C.-Z., 2005. Micro-RNAs as Oncogenes and Tumour Suppressors. *N. Engl. J. Med.* 1768–1771.
- Chen, X., Gu, S., Chen, B.F., Shen, W.L., Yin, Z., Xu, G.W., Hu, J.J., Zhu, T., Li, G., Wan, C., Ouyang, H.W., Lee, T.L., Chan, W.Y., 2015. Nanoparticle delivery of stable miR-199a-5p agomir improves the osteogenesis of human mesenchymal stem cells via the HIF1a pathway. *Biomaterials* 53: 239–250.
- Corney, D.C., Nikitin, A.Y., 2008. microRNA and Ovarian Cancer. *Histol Histopathol.* 23: 1161–1169.
- Csaba, N., Köping-Höggård, M., Alonso, M.J., 2009. Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. *Int. J. Pharm.* 382: 205–214.
- Dedes, K.J., Natrajan, R., Lambros, M.B., Geyer, F.C., Lopez-Garcia, M.A., Savage, K., Jones, R.L., Reis-Filho, J.S., 2011. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. *Eur. J. Cancer* 47: 138–150.

- Donzelli, S., Cioce, M., Muti, P., Strano, S., Yarden, Y., Blandino, G., 2016. MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. *Semin. Cell Dev. Biol.* 50: 133–142.
- Elgadir, M.A., Uddin, M.S., Ferdosh, S., Adam, A., Chowdhury, A.J.K., Sarker, M.Z.I., 2015. Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: A review. *J. Food Drug Anal.* 23: 619–629.
- Faraoni, I., Antonetti, F.R., Cardone, J., Bonmassar, E., 2009. miR-155 gene: A typical multifunctional microRNA. *Biochim. Biophys. Acta - Mol. Basis Dis.* 1792: 497–505.
- Fazi, F., Racanicchi, S., Zardo, G., Starnes, L.M., Mancini, M., Travaglini, L., Diverio, D., Ammatuna, E., Cimino, G., Lo-Coco, F., Grignani, F., Nervi, C., 2007. Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO Oncoprotein. *Cancer Cell* 12: 457–466.
- Ferlay, J., Soerjomataram I, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman D, D., Bray, F., 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: E359-386.
- Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z. a., Brenner, H., Dicker, D.J., Chimed-Orchir, O., Dandona, R., Dandona, L., Fleming, T., et al., 2017. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden. *JAMA Oncol.* 3: 524–548.
- Freier, T., Koh, H.S., Kazazian, K., Shoichet, M.S., 2005. Controlling cell adhesion and degradation of chitosan films by N-acetylation. *Biomaterials* 26: 5872–5878.
- Gaur, S., Wen, Y., Song, J.H., Parikh, N.U., Lingegowda, S., Shi, Y., Lopez-berestein, G., Frigo, D.E., Sood, A.K., 2015. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget* 6: 29161–29177.
- Gironella, M., Seux, M., Xie, M.-J., Cano, C., Tomasini, R., Gommeaux, J., Garcia, S., Nowak, J., Yeung, M.L., Jeang, K.-T., Chaix, A., Fazli, L., Motoo, Y., Wang, Q., Rocchi, P., Russo, A., Gleave, M., Dagorn, J.-C., Iovanna, J.L., Carrier, A., Pebusque, M.-J., Dusetti, N.J., 2007. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. *Proc. Natl. Acad. Sci.* 104: 16170–16175.
- Graham, K., Hakam, Y., Kaza, N., Mikhail, M., Doherty, R.M., Tasker, R., Torode, J., Von der Muhill, V., 2016. World cancer declaration: Progress report 2016, Union for

international cancer control.

- Gulyaeva, L.F., Kushlinskiy, N.E., 2016. Regulatory mechanisms of microRNA expression. *J. Transl. Med.* 14: 1–10.
- Hayes, J., Peruzzi, P.P., Lawler, S., 2014. MicroRNAs in cancer: Biomarkers, functions and therapy. *Trends Mol. Med.* 20: 460–469.
- Hemann, M.T., Lowe, S.W., 2006. The p53-Bcl-2 connection. *Cell Death Differ.* 13: 1256–1259.
- Holzerny, P., Ajdini, B., Heusermann, W., Bruno, K., Schuleit, M., Meinel, L., Keller, M., 2012. Biophysical properties of chitosan/siRNA polyplexes: Profiling the polymer/siRNA interactions and bioactivity. *J. Control. Release* 157: 297–304.
- Huang, M., Fong, C.W., Khor, E., Lim, L.Y., 2005. Transfection efficiency of chitosan vectors: Effect of polymer molecular weight and degree of deacetylation. *J. Control. Release* 106: 391–406.
- Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.G., Alder, H., Calin, G.A., Ménard, S., Croce, C.M., 2007. MicroRNA signatures in human ovarian cancer. *Cancer Res.* 67: 8699–8707.
- Jansen, A.P., Camalier, C.E., Colburn, N.H., 2005. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. *Cancer Res.* 65: 6034–6041.
- Jansson, M.D., Lund, A.H., 2012. MicroRNA and cancer. *Mol. Oncol.* 6: 590–610.
- Jayson, G.C., Kohn, E.C., Kitchener, H.C., Ledermann, J. a., 2014. Ovarian cancer. *Lancet* 384: 1376–1388.
- Kaban, K., Salva, E., Akbuga, J., 2016. In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells. *Nucleic Acid Ther.* 00: 1–11.
- Karimi, M., Avci, P., Ahi, M., Gazori, T., Hamblin, M.R., Naderi-Manesh, H., 2013. Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p- shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study. *J Nanopharm Drug Deliv.* 1: 266–278178.
- Katas, H., Alpar, H.O., 2006. Development and characterisation of chitosan nanoparticles for siRNA delivery. *J. Control. Release* 115: 216–225.
- Kent, O.A., Mendell, J.T., 2006. A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. *Oncogene* 25: 6188–6196.

- Kharia, A.A., Singhai, A.K., Verma, R., 2012. Formulation and Evaluation of Polymeric Nanoparticles of an Antiviral Drug for Gastroretention. *Int. J. Pharm. Sci. Nanotechnol.* 4: 1557–1562.
- Kinose, Y., Sawada, K., Nakamura, K., Kimura, T., 2014. The Role of microRNAs in Ovarian Cancer. *BioMed Res. Int* 14: 1–11.
- Kong, Y.W., Ferland-McCollough, D., Jackson, T.J., Bushell, M., 2012. MicroRNAs in cancer management. *Lancet Oncol.* 13: 249–258.
- L Hollis, R., Gourley, C., L Hollis, R., Gourley, C., 2016. Genetic and molecular changes in ovarian cancer. *Cancer Biol. Med.* 13: 236–247.
- Lan, H., Lu, H., Wang, X., Jin, H., 2015. MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges. *Biomed Res. Int.* 2015: 1–17.
- Lee, J.-W., Bae, S.-H., Jeong, J.-W., Kim, S.-H., Kim, K.-W., 2004. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. *Exp. Mol. Med.* 36: 1–12.
- Lehmann, U., Hasemeier, B., Christgen, M., Muller, M., Romermann, D., Langer, F., Kreipe, H., 2008. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. *J. Pathol.* 214: 17–24.
- Li, W., Zhou, J., Xu, Y., 2015. Study of the in vitro cytotoxicity testing of medical devices. *Biomed. Reports* 3: 617–620.
- Lin, M.H., Chen, Y.Z., Lee, M.Y., Weng, K.P., Chang, H.T., Yu, S.Y., Dong, B.J., Kuo, F.R., Hung, L.T., Liu, L.F., Chen, W.S., Tsai, K.W., 2018. Comprehensive identification of microRNA arm selection preference in lung cancer: MiR-324-5p and -3p serve oncogenic functions in lung cancer. *Oncol. Lett.* 15: 9818–9826.
- Liu, J., Liu, X., Ma, W., Kou, W., Li, C., Zhao, J., 2018. Anticancer activity of cucurbitacin-A in ovarian cancer cell line SKOV3 involves cell cycle arrest, apoptosis and inhibition of mTOR/PI3K/Akt signaling pathway. *J. BUON.* 23: 124–128.
- Lu, Z., Liu, M., Stribinskis, V., Klinge, C.M., Ramos, K.S., Colburn, N.H., Li, Y., 2008. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. *Oncogene* 27: 4373–4379.
- Lum, E., Vigliotti, M., Banerjee, N., Cutter, N., Wrzeszczynski, K.O., Khan, S., Kamalakaran, S., Levine, D. a., Dimitrova, N., Lucito, R., 2013. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. *Gynecol. Oncol.* 130: 369–376.

- Mansouri, S., Lavigne, P., Corsi, K., Benderdour, M., Beaumont, E., Fernandes, J.C., 2004. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy 57: 1–8.
- Mao, S., Sun, W., Kissel, T., 2010. Chitosan-based formulations for delivery of DNA and siRNA. *Adv. Drug Deliv. Rev.* 62: 12–27.
- Martien, R., Loretz, B., Sandbichler, A.M., Schnürch, A.B., 2008. Thiolated chitosan nanoparticles: Transfection study in the Caco-2 differentiated cell culture. *Nanotechnology* 19: 1–9.
- Mattiske, S., Suetani, R.J., Neilsen, P.M., Callen, D.F., 2012. The oncogenic role of miR-155 in breast cancer. *Cancer Epidemiol. Biomarkers Prev.* 21: 1236–1243.
- Mayr, C., Hemann, M.T., Bartel, D.P., 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. *Science* (80-.). 315: 1576–1579.
- Meng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J.T., Jiang, J., Schmittgen, T.D., Patel, T., 2006. Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell Lines. *Gastroenterology* 130: 2113–2129.
- Merritt, W.M., Lin, Y.G., Liz Y. Han, M.D., Aparna A. Kamat, M.D., Whitney A. Spannuth, M.D., Rosemarie Schmandt, P.D., Diana Urbauer, M.S., Len A. Pennacchio, Ph.D., Jan-Fang Cheng, P.D., Alpa M. Nick, M.D., Michael T. Deavers, M.D., Alexandra Mourad-Zeidan, M.S., Hua Wang, P.D., Peter Mueller, Ph.D., Marc E. Lenburg, P.D., Joe W. Gray, P.D., Samuel Mok, P.D., Michael J. Birrer, M.D., P.D., Gabriel Lopez-Berestein, M.D., Robert L. Coleman, M.D., Menashe Bar-Eli, Ph.D., A., Anil K. Sood, M., 2008. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. *N. Engl. J. Med.* 359: 2641–2650.
- Mohammed, M.A., Syeda, J.T.M., Wasan, K.M., Wasan, E.K., 2017. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. *Pharmaceutics* 9: 1–26.
- Negrini, M., Ferracin, M., Sabbioni, S., Carlo, M.C., 2007. MicroRNAs in cancer: from research to therapy. *J. Cell Sci.* 120: 1833–1840.
- Nguyen, D.D., Chang, S., 2018. Development of novel therapeutic agents by inhibition of oncogenic microRNAs. *Int. J. Mol. Sci.* 19: 1–17.
- Nguyen, L., Cardenas-Goicoechea, S.J., Gordon, P., Curtin, C., Momeni, M., Chuang, L., Fishman, D., 2013. Biomarkers for early detection of ovarian cancer. *Women's Heal.* 9: 171–187.
- Nidhin, M., Indumathy, R., Sreeram, K.J., Nair, B.U., 2008. Synthesis of iron oxide

- nanoparticles of narrow size distribution on.pdf>. *Bull. Mater. Sci.* 31: 93–96.
- Pellegrino, T., Sperling, R.A., Alivisatos, A.P., Parak, W.J., 2008. Gel Electrophoresis of Gold-DNA Nanoconjugates. *J. Biomed. Biotechnol.* 2007: 1–9.
- Phan, L.M., Yeung, S.-C.J., Lee, M.-H., 2014. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. *Cancer Biol Med* 11: 1–19.
- Poltronieri, P., D’Urso, P.I., Mezzolla, V., D’Urso, O.F., 2013. Potential of Anti-Cancer Therapy Based on Anti-miR-155 Oligonucleotides in Glioma and Brain Tumours. *Chem. Biol. Drug Des.* 81: 79–84.
- Qin, J., Liu, Y., Lu, Y., Liu, M., Li, M., Li, J., Wu, L., 2017. Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression. *Sci. Rep.* 7: 1–12.
- Qin, W., Ren, Q., Liu, T., Huang, Y., Wang, J., 2013. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. *FEBS Lett.* 587: 1434–1439.
- Quiñones-Lombraña, A., Blanco, J.G., 2015. Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM). *Biochim. Biophys. Acta - Mol. Basis Dis.* 1852: 1420–1427.
- Rabinovich, A., Medina, L., Piura, B., Segal, S., Huleihel, M., 2007. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. *Anticancer Res.* 27: 267–272.
- Raemdonck, K., Martens, T.F., Braeckmans, K., Demeester, J., De Smedt, S.C., 2013. Polysaccharide-based nucleic acid nanoformulations. *Adv. Drug Deliv. Rev.* 1–25.
- Ragelle, H., Vandermeulen, G., Pr at, V., 2013. Chitosan-based siRNA delivery systems. *J. Control. Release* 172: 207–218.
- Reid, G., Kao, S.C., Pavlakis, N., Brahmhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., Van Zandwijk, N., 2016. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. *Epigenomics* 8: 1079–1085.
- Rennie, W., Kanoria, S., Liu, C., Mallick, B., Long, D., Wolenc, A., Carmack, C.S., Lu, J., Ding, Y., 2016. STarMirDB: A database of microRNA binding sites. *RNA Biol.* 13: 554–560.
- Resnick, K.E., Alder, H., Hagan, J.P., Richardson, D.L., Croce, C.M., Cohn, D.E., 2009. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. *Gynecol. Oncol.* 112: 55–59.

- Rupaimoole, R., Slack, F.J., 2017. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat. Rev. Drug Discov.* 16: 203–221.
- Sadri, N., Zhang, P.J., 2013. Hypoxia-inducible factors: Mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas. *Cancers (Basel).* 5: 320–333.
- Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C., Coetzee, G.A., Jones, P.A., 2006. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell* 9: 435–443.
- Santos-Carballal, B., Aaldering, L.J., Ritzefeld, M., Pereira, S., Sewald, N., Moerschbacher, B.M., Götte, M., Goycoolea, F.M., 2015. Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. *Sci. Rep.* 5: 1–15.
- Semenza, G.L., 2003. Targeting HIF-1 for cancer therapy. *Nat. Rev. Cancer* 3: 721–732.
- Semenza, G.L., 2002. HIF-1 and tumor progression: Pathophysiology and therapeutics. *Trends Mol. Med.* 8: 62–67.
- Shah, M.Y., Ferrajoli, A., Sood, A.K., Lopez-Berestein, G., Calin, G.A., 2016. microRNA Therapeutics in Cancer — An Emerging Concept. *EBioMedicine* 12: 34–42.
- Shenouda, S.K., Alahari, S.K., 2009. MicroRNA function in cancer: Oncogene or a tumor suppressor? *Cancer Metastasis Rev.* 28: 369–378.
- Siegel, R.L., Miller, K.D., Jemal, A., 2017. Cancer Statistics , 2017. *CA Cancer J. Clin.* 00: 1–24. doi:10.3322/caac.21387.
- Sumadi, F. agung N., 2018. Formulasi Nanopartikel Kitosan Berbasis MikroRNA Sebagai Terapi Tertarget Molekular Pada Kultur Sel Kanker Ovarium. *ETD UGM.*
- Sundarbose, K., Kartha, R., Subramanian, S., 2013. MicroRNAs as Biomarkers in Cancer. *Diagnostics* 3: 84–104.
- Szender, J.B., Emmons, T., Belliotti, S., Dickson, D., Khan, A., Morrell, K., Khan, a. N.M.N., Singel, K.L., Mayor, P.C., Moysich, K.B., Odunsi, K., Segal, B.H., Eng, K.H., 2017. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. *Gynecol. Oncol.* 146: 491–497.
- Tang, B., Xu, A., Xu, J., Huang, H., Chen, L., Su, Y., Zhang, L., Li, J., Fan, F., Deng, J., Tang, L., Sun, C., Hu, Y., 2018. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. *Int. J. Cancer* 142: 109–120.

- Tang, M.X., Szoka, F.C., 1997. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. *Gene Ther.* 4: 823–832.
- Taylor, D.D., Gercel-Taylor, C., 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol. Oncol.* 110: 13–21.
- Teplyuk, N.M., Uhlmann, E.J., Gabriely, G., Volfovsky, N., Wang, Y., Teng, J., Karmali, P., Marcusson, E., Peter, M., Mohan, A., Kraytsberg, Y., Cialic, R., Chiocca, E.A., Godlewski, J., Tannous, B., Krichevsky, A.M., 2016. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. *EMBO Mol. Med.* 8: 268–287.
- Thomson, D.W., Bracken, C.P., Szubert, J.M., Goodall, G.J., 2013. On Measuring miRNAs after Transient Transfection of Mimics or Antisense Inhibitors. *PLoS One* 8: 1–7.
- Torpy, J.M., 2015. Ovarian Cancer. *J. Am. Med. Assoc.* 305: 2484.
- Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y., Tokino, T., 2008. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. *Cancer Res.* 68: 4123–4132.
- Trang, P., Medina, P.P., Wiggins, J.F., Ruffino, L., Kelnar, K., Omotola, M., Homer, R., Brown, D., Bader, A.G., Weidhaas, J.B.A., Slack, F.J., 2010. Regression of murine lung tumors by the let-7 microRNA. *Oncogene* 29: 1580–1587.
- Walker, J.M., 2009. Micro and Nano Technologies in Bioanalysis: Method and Protocol. Humana Press, Hertfordshire, UK.
- Wigerup, C., Pählman, S., Bexell, D., 2016. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. *Pharmacol. Ther.* 164: 152–169.
- Wiggins, J.F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., Bader, A.G., 2010. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. *Cancer Res.* 70: 5923–5930.
- Wu, Y. ling, Mehew, J.W., Heckman, C.A., Arcinas, M., Boxer, L.M., 2001. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. *Oncogene* 20: 240–251.
- Xu-Monette, Z.Y., Jeffrey Medeiros, L., Li, Y., Orlowski, R.Z., Andreeff, M., Bueso-Ramos, C.E., Greiner, T.C., McDonnell, T.J., Young, K.H., 2012. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. *Blood* 119: 3668–3683.
- Xu, H.S., Zong, H.L., Shang, M., Ming, X., Zhao, J.P., Ma, C., Cao, L., 2014. MiR-324-5p

- inhibits proliferation of glioma by target regulation of GLI1. *Eur. Rev. Med. Pharmacol. Sci.* 18: 828–832.
- Yeo, Y., Park, K., 2004. Control of Encapsulation Efficiency and Initial Burst in Polymeric Microparticle Systems. *Arch Pharm Res Vol* 27: 1–12.
- Zhang, B., Pan, X., George, P.C., Anderson, T.A., 2013. MicroRNAs as Oncogenes and Tumor Suppressors. *Dev. Biol.* 302: 1–12.
- Zhang, L., Lv, R., Qu, X., Chen, X., Lu, H., Wang, Y., 2017. Aloesin Suppresses Cell Growth and Metastasis in Ovarian Cancer SKOV3 Cells through the Inhibition of the MAPK Signaling Pathway. *Anal. Cell. Pathol. (Amst)*. 2017: 8158254.
- Zhang, S., Lu, Z., Unruh, a. K., Ivan, C., Baggerly, K. a., Calin, G. a., Li, Z., Bast, R.C., Le, X.-F., 2015. Clinically Relevant microRNAs in Ovarian Cancer. *Mol. Cancer Res.* 13: 393–401.
- Zhang, X.F., Tu, R., Li, K., Ye, P., Cui, X., 2017. Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer. *J. Cell. Biochem.* 118: 3391–3400.
- Zhu, S., Si, M.L., Wu, H., Mo, Y.Y., 2007. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). *J. Biol. Chem.* 282: 14328–14336.